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Abstract
Gestational diabetes mellitus occurs in up to 10% of pregnancies and often leads to labor
and delivery complications for both the mother and the baby. Early identification of
gestational diabetes and educational intervention are needed to improve the selfmanagement and knowledge among pregnant women. The purpose of the project was to
implement newly established national guidelines to ensure that women with gestational
diabetes are identified during the first trimester of pregnancy and begin diabetes
education early in gestation. Lewin’s planned change theory was selected as the
theoretical framework, and the six sigma approach was used to facilitate the change
process. The project used a pretest and posttest design in a convenience sample of 35
women with gestational diabetes who were referred for the educational intervention and
completed the education and the questionnaires. The anticipated outcomes were for (a)
women to be screened during the first trimester of their pregnancy and (b) the post
education scores on the self-management questionnaire to demonstrate an increase in
knowledge about contacting the provider for abnormal blood sugar results and making
appropriate dietary choices. Data were entered into SPSS and were analyzed using
descriptive statistics. A t test was used to compare pretest and posttest knowledge scores.
During the project, 57% of the participants were screened in the first trimester of
pregnancy. The difference in the pretest (M = 75.43) and the posttest scores (M = 91.71)
was statistically significant (p < .0001). These findings have important social change
implications because early screening and early intervention will help to reduce birth
complications and long-term development of Type 2 diabetes.
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Section 1: Project Overview
Screening and Intervention for Women With Hyperglycemia During Pregnancy
Hyperglycemia during pregnancy is a serious but common complication of pregnancy that
is associated with poor labor and delivery outcomes for both the mother and the baby.
Gestational diabetes mellitus (GDM) is often defined as hyperglycemia identified during
pregnancy or as an intolerance of carbohydrates during pregnancy. Overt or pregestational
diabetes refers to any type of diabetes diagnosed prior to pregnancy. It is estimated that GDM
occurs in 4.8% of pregnant women according to a Centers for Disease Control and Prevention
(CDC) prevalence report in 2009; however, the international Hyperglycemia and Adverse
Pregnancy Outcomes (HAPO) study demonstrated that 6.7% of pregnant women met the
Carpenter and Coustan (CC) criteria for GDM (Agency for Healthcare Research and Quality
[AHRQ], 2012). In 1982, the CC criteria recommended that women with fasting plasma glucose
levels greater than or equal to 95 mg/dL receive a diagnosis of GDM (Carpenter & Coustan,
1982). The International Association of the Diabetes in Pregnancy Study Group (IADPSG; 2010)
reported that 17.8% of women were diagnosed with GDM as a result of their lower glucose
threshold (i.e., plasma glucose levels greater than or equal to 92 mg/dL.) The IADPSG also
recommended screening all or at least high-risk women at their first prenatal visit with a random
plasma glucose, HbA1C, or random blood sugar to help identify undiagnosed pre-existing
diabetes prior to pregnancy (IADPSG, 2010).
The HAPO study was an observation study that examined the various relationships of
GDM and obesity with pregnancy outcomes. The study began with 53,295 eligible women from
15 centers in nine countries with 23,316 of those women agreeing to participate and completing
the study between July 2000 and April 2006. Participants and caregivers were blinded to glucose
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values, and no recommendations were made to alter diet or other treatments related to glucose
intolerance or obesity. The participants underwent a 75-gram oral glucose tolerance test (OGTT)
between 24 and 32 weeks, and GDM was diagnosed utilizing the IADPSG criteria. The HAPO
study determined that GDM and obesity are associated with adverse pregnancy outcomes, but the
combination of GDM and obesity has a much greater effect (IADPSG, 2012).
In addition, screening at the first prenatal visit will help identify gestational diabetes and
the undiagnosed overt diabetic early in the pregnancy, which will allow for interventions and
treatment to start in the first trimester versus the third trimester (Metzger, 2010). Providing
intervention in the first trimester could have a direct effect on macrosomia and large for
gestational age (LGA) rates, which could also prevent future cases of Type 2 diabetes mellitus in
both the mother and the infant.
The current GDM guidelines for Winchester Medical Center (WMC), the site for the
current project, were established in 1999 and need revision. In particular, the guidelines do not
align with national screening guidelines related to hyperglycemia in pregnancy. Obstetricians at
WMC were utilizing the American Diabetes Association (ADA) and American College of
Obstetrics and Gynecology (ACOG) screening guidelines for hyperglycemia in pregnancy based
on the CC criteria. With the ADA and ACOG screening guidelines, the LGA rate for deliveries is
27% (WMC, 2011). The goal is for this number to be as close to zero as possible to prevent
adverse labor and delivery outcomes for the mother and baby.
To address these issues, a team of nurses and maternal and fetal medicine physicians
reviewed the recommendations of national guidelines to develop new practice guidelines for the
organization. Because there are varying recommendations, the team believed that research on the
effectiveness of any new guidelines within WMC was needed. The team reviewed the literature
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on GDM screening recommendations and decided to revise the guidelines to reflect many of the
IADPSG recommendations, including screening all pregnant women at the first prenatal visit
with a HbA1C and adopting the lower threshold for diagnosis to plasma glucose levels of 92
mg/dL for OGTT. Please refer to Appendix B for full details of the pregnancy and diabetes
guidelines.
Establishing a standardized screening guideline is expected to provide consistency in
hyperglycemia screening among all pregnant women seen at the center and to allow for earlier
diagnosis and intervention for both overt diabetes and GDM. Once a patient is diagnosed with
diabetes of any type, interventions may begin, which include referral to the Diabetes
Management Program (DMP) for education on meal planning, self-monitoring blood glucose,
and monitoring daily urine for ketones. Interventions also include referral to maternal and fetal
medicine specialists for follow up related to high-risk pregnancy and, possibly, prescription
medications if necessary. Tight glycemic control throughout the pregnancy may reduce
complications such as LGA, macrosomia, caesarian section, shoulder dystocia, and infant
hypoglycemia; therefore, the length of stay for both the mother and the baby will be decreased
and infant admission to the neonatal intensive care unit (NICU) may be completely avoided
(IADPSG, 2010).
Providing obstetricians with solid guidelines for managing hyperglycemia in pregnancy
may improve their compliance and tighter glycemic control for the patients. Nurses within the
DMP will provide GDM patients with proper education on diet, testing blood sugars and ketones,
and instructions on when to notify their physician regarding blood sugar values. Follow-up for
blood sugar values and ketone results will be the responsibility of the obstetrician or the maternal
fetal medicine specialist.
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Background
Risk factors related to GDM vary but often include older maternal age, higher body mass
index (BMI), polyhydramnios, past history of GDM, macrosomia in previous pregnancy, and
family history of diabetes; further, ethnic groups with increased risk for developing Type 2
diabetes, such as Hispanics; Africans; Native Americans; and South, East Asian, or Pacific
Islanders have a higher risk of GDM (AHRQ, 2012). However, modifiable risk factors are also
associated with GDM, which include obesity, diets high in saturated fat, physical inactivity, and
smoking. The combination of modifiable risk factors and the societal trend of older maternal age
contribute to increase the prevalence of GDM (Ferrara, 2007).
Complications associated with GDM for the infant include LGA, macrosomia, shoulder
dystocia, prematurity, and infant hypoglycemia. These complications may increase the length of
stay for the infant and may even require the infant to be admitted to the NICU for observation or
possibly an extended period (ACOG, 2011). Complications for the mother include hypertension,
preeclampsia, episiotomy, and cesarean section delivery. These complications may lead to
premature labor, hemorrhage, and changes in the delivery plan from vaginal to cesarean section
due to the increased size of the infant. Each of these complications may result in an increased
length of stay for the mother requiring additional treatments and interventions (U. S. Preventive
Services Task Force [USPSTF], 2013).
Problem Statement
The problem addressed by this project was the need for early identification of GDM and
educational intervention to improve the self-management and knowledge of pregnant women.
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Project Purpose
The purpose of this project was to use newly established guidelines for screening
hyperglycemia in pregnancy to ensure that patients with GDM will be identified during their first
trimester and begin education and other interventions/treatments earlier in gestation in the clinic
setting. The project proposed that early detection of gestational diabetes and early referral for
diabetes education would improve the self-management and knowledge of pregnant women
diagnosed with GDM. Although beyond the scope of this project, the ultimate goal was to reduce
complications associated with GDM such as preterm labor, hypertension, preeclampsia,
hemorrhage, and shoulder dystocia, while decreasing adverse labor, delivery, and infant
outcomes such as macrosomia, LGA, cesarean delivery, and infant hypoglycemia.
In addition to decreasing complication rates and improving outcomes, the early diagnosis
and intervention may also improve future outcomes related to GDM such as the development of
Type 2 diabetes in both the mother and the baby. By reducing the prevalence of GDM, fewer
mothers will have an increased risk for developing Type 2 diabetes in the future. Fewer infants
born with macrosomia and LGA will also reduce the number of infants at risk of developing
Type 2 diabetes in the future. For women identified with GDM, the new guidelines establish
criteria for follow-up blood glucose testing with their primary physician after delivery to monitor
for the development of Type 2 diabetes.
Project Outcomes
The anticipated outcomes of the project were:
1. Women receiving care in the project clinic will be screened for GDM during the first
trimester of their pregnancy.

6
2. The pretest scores compared to the posttest scores on a questionnaire to examine
knowledge of GDM and its treatment will demonstrate that the participating patients have
learned when to contact their physician for abnormal blood sugar results and appropriate
dietary choices.
Frameworks of the Project
Kurt Lewin’s planned change theory was selected as the theoretical framework for the
project. Lewin’s theory includes three elements: field theory, group dynamics, and the three-step
model. Field theory and group dynamics are utilized during the three-step model of unfreezing,
moving, and refreezing to create and maintain change (Burnes, 2009). Changing one’s
views/perceptions is referred to as the process of unfreezing. The next stage is changing the
thoughts, feelings, and/or behaviors of the providers to introduce the revised practice guidelines.
The final stage is refreezing, which incorporates the changes and allows them to become the new
standard practice for all GDM patients (Kaminski, 2011).
The providers at the clinical site needed to understand that the current GDM guidelines
were antiquated and in need of revision to ensure optimal patient outcomes. Changing the
providers’ views/perceptions of the current GDM guidelines was Step 1, unfreezing. The next
step was changing the thoughts, feelings, and/or behaviors of the providers to introduce the
revised practice guidelines. The final step was refreezing, which incorporates the changes and
allows them to become the formal new standards of practice for all GDM patients (Kaminski,
2011).
Planned change was also applicable to the pregnant woman with the new diagnosis of
GDM. During the unfreezing step the woman attended a class on GDM that addressed various
challenges such as learning about diabetes, a new diet, and an exercise plan, and monitoring
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blood sugars and ketones. The next step was changing their behaviors and adhering to the new
diet, exercise, and monitoring regimen as recommended by the DMP and the patients’
obstetrician. The final step was refreezing, which allowed the women to accept the changes in
diet and exercise and the monitoring of blood sugars and ketones as their new way of life. It was
important for the mothers to understand the importance of continuing to watch their diet and to
exercise to help prevent or delay the onset of Type 2 diabetes in the future.
The six sigma approach was utilized for program evaluation. In health care, it is
important to include the patients’ perspectives or opinions regarding programs. One method was
to complete pretests and posttests to measure the effectiveness and/or satisfaction with the
service provided. Six sigma utilizes the DMAIC methodology, which stands for define, measure,
analyze, improve, and control. The process begins with defining the goal and overall scope of the
project and then creating baseline evidence for comparison. The purpose of the next phase
(measure) was to continuously monitor the performance and collect data that were used to
analyze and interpret whether the performances and/or outcomes are as expected (analyze) or if
change needed to be made (improve). The final stage (control) was to remove the actual cause of
the problem so the focus could stay on the actual improvement (Brandyopadhyay & Coppens,
2005).
With regard to hyperglycemia in pregnancy, the six sigma approach provided the
evaluation plan/tool to determine the effectiveness of the education presented to the project
participants. Continuous clinical support and evaluation took place, whereas pretests and
posttests were utilized to evaluate the patients’ perceptions and knowledge related to the
education intervention. On completion of data collection, I analyzed the data and determined
recommendations for revisions to the guidelines as deemed necessary.
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Nature of the Project
The project used a pretest and posttest design in a convenience sample of women with
GDM who were referred for an educational intervention and agreed to complete the education
and the questionnaires. The pretest was completed on arrival for the first of three education
sessions on meal planning, self-monitoring blood glucose, and self-monitoring daily urine for
ketones, possible prescribed diabetic medications, and when to notify the physician. On
completion of the education, the women completed the posttest and client satisfaction survey.
The educator conducting the class reviewed the answers to the test to ensure appropriate
understanding and to ensure a positive learning experience.
WMC is one of six nonprofit hospitals within Valley Health (VH). WMC is a designated
magnet hospital with 445 beds and is located in Winchester, Virginia. In 2012, WMC reported
255 live births to women with GDM; in 2013, WMC reported 278 live births to women with
GDM; and in 2014 WMC reported 373 live births to women with GDM. The 2013 and 2014 data
demonstrate a significant increase in GDM prevalence at WMC if current GDM birth trends
continue. The WMC cesarean section rate in 2012 was 33.2%, which is slightly higher than the
national average of 32.8% (Martin, Hamilton, Ventura, Osterman, & Mathews, 2011). However,
the cesarean section rate in 2012 for women with GDM was 44%. At Valley Health, both
macrosomia and LGA rates are on the rise. Macrosomia rates increased significantly from 6% in
2011 to 11.6% in 2012 and 11% in 2013. In addition, LGA rates have increased from 25% in
2011 to 27.3% in 2012 and 27.7% in 2013. In 2012 at WMC, 27 neonates required treatment to
address hypoglycemia, whereas in 2013 at WMC, 25 neonates required treatment for
hypoglycemia. In 2012, eight of those neonates required admission to the NICU to manage
serious complications associated with infant hypoglycemia and GDA and seven of those
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neonates required NICU admission in 2013. As LGA and macrosomia are not reportable
statistics for neonates, no date is available for comparison on the state, regional, or national level.
Definition of Terms
Diabetes mellitus (DM) is a group of diseases that affect how the body uses glucose (Van
Leeuwen et al., 2013).
Diabetes management program (DMP) is an outpatient diabetes program through WMC
that provides education and other resources related to Type 1, Type 2, and gestational diabetes
mellitus.
Fasting blood glucose (FBG) is a blood test after a minimum of 8 hours with no caloric
intake. It is used to confirm a diagnosis of diabetes mellitus (Van Leeuwen et al., 2013)
GCK is a common genetic variant associated with high blood glucose levels (Freathy et
al., 2010).
Gestational diabetes mellitus (GDM) is hyperglycemia first diagnosed in pregnancy
(Ferrara, 2007).
Glycated hemoglobin (HbA1C) is the average blood glucose levels over the previous 3
months. It is used to monitor effectiveness of treatment over a long period of time (Van Leeuwen
et al., 2013).
Large for gestational age (LGA) is birth weight greater than the 90th percentile for their
gestational age (Ricci, Kyle, & Carman, 2013).
Macrosomia is birth weight greater than 4000 grams or 8 pounds, 13 ounces (Ricci et al.,
2013).
Oral glucose tolerance test (OGTT) measures the body’s ability to metabolize glucose. It
is used to diagnose diabetes mellitus (LeMone, Burke, & Bauldoff, 2011).
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Multiparity is the birth of two or more children (Ricci et al., 2013).
Polyhydramnios is an excessive amount of amniotic fluid in the uterus (Mayo Clinic,
2011).
TCF7L2 is a common genetic variant associated with higher blood glucose levels
(Freathy et al., 2010).
Project Assumptions
During the project, I presumed patient truthfulness and honesty in completion of the
pretest and posttest questionnaires and client satisfaction surveys. I also presume provider
compliance with the new guideline (see Appendix E) regarding the type and timing of the GDM
screening. Using the new recommendations, I presumed providers would screen for GDM at the
first prenatal visit utilizing HgA1C, which would lead to an earlier referral for intervention for
those individuals with a positive hyperglycemia screening. In addition, interventions to improve
glycemic control would also begin at an earlier point in pregnancy compared with the previously
used guidelines.
Project Limitations
One main limitation of this project was related to the correctness of data being entered by
the registered nurses (RNs) regarding the timing of glucose screening for GDM. The computer
program is standardized, but if the RNs did not complete the screening section in its entirety,
testing and results may be omitted therefore limiting the availability of data. Even though the
diabetes class content was consistent, the presentation may vary based on the RN or dietician
teaching the class; therefore, a second limitation may exist due to inconsistencies in client
learning based on teaching styles. A third limitation was that the study population is a
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convenience sample. Therefore, generalization to the population was limited and selection bias
was a possibility.
Evidence-Based Significance of the Project
Type 2 diabetes is serious chronic health issue affecting 25.8 million children and adults
in the United States. One in every 400 children and adolescents has diabetes, which converts to
0.26% of persons under 20 years of age in this country having diabetes. Diabetes is associated
with high levels of morbidity and premature mortality, contributing to 231,404 deaths in 2007.
Complications associated with diabetes include heart disease, stroke, high blood pressure,
blindness, kidney disease, neuropathy, and amputations (CDC, 2011). As a result of diabetes and
the associated complications, the cost of health care in those diagnosed with diabetes is 2.3 times
higher than in those without diabetes. In the U. S., the total cost of health care for diabetic
patients was $245 billion in 2012 (American Diabetes Association [ADA], 2013).
GDM occurs in 2% to 10% of pregnancies, with 5% to 10% of those women being
diagnosed with diabetes, usually Type 2, immediately after pregnancy (CDC, 2011). As the
number of cases of GDM increases, the potential labor and delivery complications and medical
costs associated with the necessary treatments for both the mother and the baby increase as well.
In addition to the increase in labor and delivery complications, it is important to consider the
increased risk to both the mother and the baby of developing Type 2 diabetes in the future.
Approximately 50% of women with GDM will develop Type 2 diabetes within 5 years of
pregnancy. Infants have an increased risk for obesity, impaired glucose tolerance, and Type 2
diabetes as children or young adults if their mother had GDM. Hyperglycemia during pregnancy
and the development of Type 2 diabetes increase the need for follow-up during pregnancy and
postpartum for both the mother and the baby to monitor for the onset of diabetes as well as
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recommended health behaviors to prevent or delay the onset of the disease. Additional resources
will need to be available to manage the increased number women with GDM and the infants born
to these women (Ferrara, 2007).
Implications for Social Change
Overt diabetes is a chronic disease linked to morbidity and premature mortality (CDC,
2011). Researchers have presented an increased risk for a mother with GDM to develop Type 2
diabetes within 5 years and current research has indicated a correlation between infants of GDM
mothers also having an increased risk for developing Type 2 diabetes (Ferrara, 2007). Early
screening and early intervention will help to reduce the baby’s birth weight, which will help to
prevent later issues with both obesity and the development of Type 2 diabetes in the child. In
addition, the mother will have better control over glucose levels, which will reduce the amount
of insulin the infant must produce, thereby reducing the risk for both the mother and the baby to
later develop Type 2 diabetes. If hyperglycemia can be avoided, both the mother and the baby
may be able to avoid Type 2 diabetes as well as all the complications associated with it. These
changes will significantly reduce the societal burden related to preventable excess diabetes.
Summary
GDM is a common complication of pregnancy with many potential adverse outcomes for
both the mother and the baby. Screening for hyperglycemia at the first prenatal visit will help to
identify overt diabetes and GDM early in the pregnancy. This will allow the mother to participate
in earlier interventions and to have improved glycemic control throughout the pregnancy
(Metzger, 2010). Specific interventions included the three-day education sessions on meal
planning, self-monitoring blood glucose, monitoring daily urine for ketones, and when to notify
the physician.
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Section 2 will provide the results of an in depth literature review related to hyperglycemia
in pregnancy. The literature review explores the research conducted regarding timing of
screening for hyperglycemia and the results that indicate a positive screening. In addition, the
literature review includes opinions and reviews of various governing bodies related to the new
practice recommendations.
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Section 2: Review of the Literature
The problem addressed by this project was whether early identification and intervention
consisting of education can improve the self-management and knowledge of pregnant women
diagnosed with GDM. The current project established, in a clinic setting, new and consistent
guidelines among Valley Health obstetricians for screening hyperglycemia in pregnancy to
ensure that patients with GDM would be identified in the first trimester and begin education and
other interventions/treatments earlier in gestation in a clinic setting. I evaluated the effectiveness
of the education through pretest and posttest questionnaires. This section will discuss the
literature search strategy, the theories utilized, and how the literature relates to current practice.
Literature Search Strategy

The search strategy objective was to identify published research articles related to
hyperglycemia in pregnancy, focusing on timing and type of diagnostic screening. I conducted a
standard search through Walden University’s library for the literature review, which involved
queries of MEDLINE, CINAHL, and the Cochrane Central Registry of Controlled Trials to
identify relevant articles written in the English language. The search included key words such as
gestational diabetes mellitus, screening, hyperglycemia, pregnancy, diabetes, and HgA1C. I used
words individually and in combination to expand the search. Relevant organizational websites
such as ACOG, AHRQP, IADPSG, and the USPSTF were also included in the literature review
to access specific organizational interpretations, reviews, and position statements with regard to
screening for hyperglycemia in pregnancy.
Eleven quantitative research articles and 13 reviews, summaries, and clinical practice
articles were included in the literature review. Nine of the articles were longitudinal casecontrolled studies, one was a randomized controlled trial, and one was a descriptive study.
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Approximately 17 identified articles were not included in the literature review due to lacking
relevance for screening for hyperglycemia in pregnancy or educational interventions related to
GDM. Specifically, articles were excluded due a focus on the effects of obesity and GDM rates
as well as a focus on inpatient treatment and/or inpatient education.

Theoretical Model
When considering practice change theories, Kurt Lewin’s planned change theory was the
optimal choice due to the project affecting change in practices of the obstetric staff, the certified
diabetes educators (CDEs), and the patients. Change often creates social conflict, and Kurt
Lewin believed that the key to resolving social conflict was planned change through learning.
Planned change enables those involved to understand the purpose and to evaluate the effect of
change in their world. Lewin’s planned approach included four elements: field theory, group
dynamics, action research, and a three-step model of change. Lewin believed that the current
state of a group of individuals, also known as status quo, is a result of the group environment or
field. The field is responsible for the perceived individual behaviors represented within the
group. When dealing with change, the focus in group dynamics should be on what is best for the
group as a whole versus the interests of any one individual. It should use the group to pressure
any isolated individual to conform to ensure the focus of change remains at the group level. In
action research, the success of change relies on the ability of individuals to understand their
environment and the effect change will have. Action research involves a process of research
causing action, which leads to evaluation and further action. Action research utilized field theory
and group dynamics to understand group behaviors as the success of change requires
participation and collaboration of the group members involved.
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The final element of Lewin’s planned change through learning involves the three-step
model of unfreezing, moving, and refreezing. Unfreezing is a challenging process that refers to
disturbing the current state or equilibrium and discarding old behaviors to provide the
opportunity for new behavior to be adopted. As unfreezing opens the door to change, the moving
step identifies and evaluates the forces at play and determines the most suitable options to move
the group toward the new behaviors. The final step, refreezing, establishes a new state of
equilibrium that includes the newly learned behaviors. When looking at change in a group or
organization, the refreezing step includes changing the culture, norms, policies, procedures, and
practices (Burnes, 2004).
With any change, time must be allowed for individuals to process the thought of change
and consider the implications, while being nudged in the direction of the proposed change.
Educating all parties to the change in practice or behavior is the second phase and must be
comprehensive to ensure comfort, competence, and participation. Through field theory, group
dynamics, and the three-step model, equilibrium is disrupted to allow for change to take place
and then re-established during the refreezing step, which helps to ensure forward progress
continues toward project goals and objectives (Burnes, 2004).

Literature Review Related to Methods
The literature review will demonstrate the previously mentioned screening test
controversy among the governing bodies, physicians, and healthcare professionals invested in the
care of women with hyperglycemia in pregnancy. Various studies address the debate of who to
screen, when to screen, and what test to utilize, whereas others focus on where the diagnostic
criteria should be set for diagnosing GDM and/or overt diabetes. Additional studies focus on the
potential complications, immediate adverse outcomes, and long-term overall health outcomes for
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both the mother and the infant. Several reviews of the current literature are provided not only to
summarize and establish the continued controversy, but also to identify the gaps in research
remain.
Longitudinal Case-Control Studies
The first of eight longitudinal case-control studies was conducted by the Hyperglycemia
and Adverse Outcomes (HAPO) study (2008) “to clarify the risks of adverse outcomes
associated with various degrees of maternal glucose intolerance less severe than that in overt
diabetes mellitus” (p. 1,991). The study included 25,505 women at 15 centers in nine countries.
The study determined that LGA and infant hyperinsulinemia were strongly associated with
maternal hyperglycemia, but cesarean section, neonatal hypoglycemia, premature delivery,
shoulder dystocia or birth injury, NICU admission, and preeclampsia also showed linear
associations with the 1-hour plasma glucose level, the 2-hour plasma glucose level, and the FBS.
Essentially, the study determined the need for current diagnostic criteria to be revised due to
significant associations with adverse outcomes and higher than expected levels of hyperglycemia
in pregnancy among those currently considered nondiabetic (HAPO, 2008).
The HAPO study (2008) was also conducted to determine if two specific common
genetic variants GCK and TCF7L2 were associated with hyperglycemia of pregnancy in
European and Asian women as they are in non-pregnant diabetic women of European and Asian
ancestry. The study determined that the GCK was associated with a higher FBS in both European
and Asian women, while the TCF7L2 was associated with higher FBS and OGTT testing results
in only the European women. In addition, according to the new IADPSG recommendations, both
the GCK and the TCF7L2 were associated with higher odds of GDM in both populations
(Freathy et al., 2010).
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Another study from HAPO (2012) was conducted to evaluate the association of GDM
and obesity with adverse pregnancy outcomes. Ultimately, the study determined that both GDM
and obesity were independently associated with adverse pregnancy outcomes such as primary
cesarean section, preeclampsia, and fetal hyperinsulinemia. In addition, when GDM and obesity
are combined, the relationship significantly increases and also includes an increased prevalence
of shoulder dystocia (Catalano et al., 2012).
A study by O’Sullivan et al. (2011) was conducted to evaluate the effect the new
diagnostic criteria defined by the IADPSG when compared to the previous WHO criteria would
have on the prevalence and the outcomes of GDM in a predominantly European population. A
total of 5,500 women were given an OGTT between 24 and 28 weeks gestation and, based on the
IADPSG criteria, 12.4% of the participants were diagnosed with GDM compared to 9.4% with
the WHO criteria. In addition, the IADPSG GDM participants were also associated with a
significant increase in adverse maternal and neonatal outcomes compared to the WHO
participants. One particular limitation of this study was that treatment for hyperglycemia was
determined by the WHO criteria not the IADPSG criteria. The study was not intended to evaluate
hyperglycemia management, but it must be considered when determining the validity of the data
(O’Sullivan et al., 2011).
A study by Katon, Reiber, Williams, Yanez, and Miller (2012) was conducted to
determine if there was an increased risk of delivering a LGA or macrosomic infant based on the
timing of the HbA1C. The study included 502 women and determined no trend of increased
LGA or macrosomia infant births based on the timing of the HgA1c or the diagnosis of GDM.
However, there was limited evidence of increased risk of delivering a LGA or macrosomia infant
among women in the highest quartile of HbA1C levels at diagnosis when compared to those
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women in the lowest quartile of HbA1C at diagnosis. In addition, when women of Asian, Indian,
or other race/ethnicity were excluded, there was a trend of increased risk of LGA or macrosomia
associated with higher HbA1C quartile at time of diagnosis. It is also important to note an
important limitation of this study was not including the effect of aggressive hyperglycemia
management on the overall results of this study (Katon et al., 2012).
A study by Cavassini, Lima, Calderon, and Rudge (2012) was conducted to estimate the
cost-benefit relationship and social benefit of treating women with hyperglycemia in the hospital
compared to outpatient care. The study determined that successful treatment of GDM avoided
costs and that outpatient management was more cost effective than hospitalization. The study
divided the patients into groups based on diet therapy or diet and insulin therapy. However, there
was no consideration for approved medication protocols in combination with diet therapy in the
outpatient category, which demonstrates a limitation to the study (Cavassini et al., 2012).
In 2012, a study by Mehta, Kruger, and Sokol was published that evaluated whether
hyperglycemia in pregnancy was a risk factor for childhood obesity. Data were collected from
493 inner-city, African-American children between the ages of 2 and 5 and their mothers. The
study did show that children born to diabetic mothers were more likely to be obese and when
other covariates associated with diabetes were included in the model, both diabetes and maternal
pre-pregnancy BMI demonstrated a significant correlation to childhood obesity. One other factor
to consider is the relationship of LGA in the model because when LGA was added into the
equation, diabetes was no longer significant in childhood obesity. However, the authors of the
study suggested that LGA is affected by diabetes in utero, therefore, having an indirect
relationship with childhood obesity (Mehta et al., 2012).
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Other Studies
A randomized controlled trial was conducted by O’Connor et al. (2012) to determine if
trimester-specific references for HbA1C should be utilized in pregnancy. A total of 311 non
diabetic Caucasian pregnant and non-pregnant women were included in the study. The study was
able to establish a reference interval of 4.8% to 5.5% for the healthy, non-pregnant woman,
which is consistent with a previous study by the International Federation of Clinical Chemistry
and Laboratory Medicine (IFCC); however, the study also determined that this was not an
appropriate reference interval to be utilized in pregnancy. In pregnancy, trimester-specific
HbA1C reference intervals were shown to be the appropriate method to manage GDM, prevent
complications associated with diabetes, or both. A normal reference interval for HbA1C in a
non-pregnant woman was determined to be 4.8% to 5.5%. The normal reference intervals for
HgA1c during pregnancy were determined to be 4.3% to 5.4% in the first trimester, 4.4% to
5.4% in the second trimester, and 4.4% to 5.4% in the third trimester (O’Connor et al., 2012).
Dall et al. (2011) conducted a quasi-experimental study to evaluate the association of
health care use and cost with the intensity of participation as well as prior uncontrolled diabetes
among their TRICARE DMP participants. A total of 37,370 participants ranging from 18 to 64
years of age were included in the study. Women were included if they had any diabetes-related
emergency department visits, hospitalizations, or more than twenty 30-day prescriptions for
diabetic medications in the previous year. The study determined that participation in the DMP
was cost effective, especially for the uncontrolled diabetics, and that active program participation
demonstrated a larger reduction in inpatient days and emergency department visits. With
program participation, inpatient days and emergency department visits decreased, while
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outpatient visits, retinal examinations, HgA1c tests, and urine microalbumin tests increased in
comparison to those of the control patients (Dall et al., 2011).
A descriptive study was conducted by Dijk et al. (2011) to evaluate what effect total
healthcare utilization had on Type 2 diabetes patients that is actually disease specific and could
be utilized in the development of a disease management program. Essentially, it was determined
that any program should be developed to assist the patient in coordinating care not to replace
coordination by the patient. In addition, it was determined that a disease management program
should focus on all chronic diseases not just diabetes, especially since many diabetics also have
other chronic conditions such as heart disease and chronic obstructive pulmonary disease (Dijk et
al., 2011).
Opinions, Reviews, and Summaries
The IADPSG was formed in 1998 to facilitate collaboration among regional and national
groups focusing on diabetes and pregnancy in an attempt to enhance quality of care by
facilitating research and advancing education related to diabetes in pregnancy. In 2008, a
workshop was sponsored by the IADPSG to review published and unpublished HAPO study
findings and other works that were related to hyperglycemia in pregnancy and infant and
maternal outcomes. A consensus panel was convened and further reviewed the HAPO study. A
consensus detection strategy for hyperglycemia in pregnancy was reached. The panel
recommended a two–phase approach. During the first phase, all or only high risk women
complete a universal screening (FBS, RBS, or HbA1C) at their first prenatal appointment
utilizing tighter diagnostic criteria such as a RBS of < 92 mg/ dL versus < 95 mg/dL. The results
indicate overt diabetes, GDM, or moving to the second phase. The second phase consists of a
fasting 75 gram, 2-hour OGTT between 24 and 28 weeks gestation for all women with a normal
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screening at their first prenatal visit or the woman who has received no screening to date for
hyperglycemia in pregnancy. The results again can indicate overt diabetes, GDM, or a normal
value. The consensus panel acknowledged that further research will be needed to determine the
cost effectiveness of treatment for GDM utilizing the IADPSG criteria, optimal glycemic targets,
appropriate follow-up of the mothers to evaluate for later development of Type 2 diabetes, and
follow-up of children to evaluate associations of maternal hyperglycemia with obesity and
altered glucose metabolism (IADPSG, 2010).
A mini review by Hadar, Oats, and Hod (2009) discussed the various controversies
surrounding GDM. Much of the controversy evolves from the lack of correlation in diagnostic
criteria to maternal and infant outcomes. The HAPO study was designed to answer some of these
controversies and, essentially, this mini review concluded that the HAPO study had already
provided answers to many of these controversies. Ultimately, the HAPO study demonstrated that
FBS and post 75 gram, 2-hour OGTT correlate to maternal, perinatal, and neonatal outcomes.
Based on this review, it is predicted that international recommendations using these criteria for
GDM diagnosis will soon be published (Hadar et al., 2009).
The USPSTF conducted a systematic review to test the various screening methods for
GDM utilizing a range of glucose threshold recommendations. Two reviewers extracted and
reviewed data from 51 cohort studies. Ultimately, the review confirmed both a FBS and an
OGTT are good at identifying women who do not have GDM, but the OGTT was better at
identifying women who do have GDM. However, data are minimal for screening prior to 24
weeks gestation, nor has any validation taken place utilizing the new IADPSG recommendations
(Donovan et al., 2013).
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In 2011, the American College of Obstetric Practice (ACOG) released a committee
opinion with their recommendations for GDM screening and diagnosis. ACOG recommended
that all women be screened for GDM, but the screening may be conducted by patient history,
clinical risk factors, or a 50-gram, 1-hour OGTT between 24 and 28 weeks gestation. Further,
ACOG continues to recommend the two-step approach utilizing the 50-gram, 1-hour OGTT
followed by the 75-gram, 2-hour OGTT to confirm GDM diagnosis compared to the 1-step
approach utilizing the 75-gram, 2-hour OGTT proposed by the IADPSG recommendation to
simplify the process for screening and diagnosing GDM (The American College of Obstetricians
and Gynecologists, 2011).
Buckley et al. (2011) reviewed the literature to evaluate the relevance of GDM, current
screening practices, and barriers to screening in Europe. The review determined a GDM
prevalence rate of 2% to 6%, which fluctuated based on patient location. Screening practices
vary across Europe due to inconsistent guidelines for testing methods, diagnostic glycemic
thresholds, and the value of routine screening. In addition poor clinician awareness of GDM, the
GDM diagnostic criteria, and variations in local guidelines also affect the detection of GDM
(Buckley et al., 2011).
An article by Ryan (2011) discussed the effects of the newly proposed diagnostic criteria
which are recommended by the IADPSG. The author suggested the criteria will increase the
prevalence of GDM to 17.8%, which is double the current number of women with GDM. In
addition, the majority of women with LGA have normal glucose levels during pregnancy based
on the criteria and the stronger predictor of LGA is maternal obesity. It is estimated using these
criteria that the GDM diagnosis would prevent an estimated 140 cases of LGA, 21 cases of
shoulder dystocia, and 16 cases of birth injury out of over 23,000 pregnancies (Ryan 2011). The
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author did not find the OGTT to be a reliable test for diagnosing mild hyperglycemia. Based on
these three factors, further debate should take place prior to implementing the proposed
recommendations (Ryan, 2011).
A review article by Cundy (2012) discussed new recommendations from the IADPSG for
diagnosis of GDM. Cundy (2012) questioned much of the research with regard to the extent to
which GDM affects particular outcomes such as cesarean section and the risk for future
development of Type 2 diabetes for both the mother and the infant. Cundy (2012) raised another
question as to the direction of research being focused on hyperglycemia in pregnancy when
possibly the focus should shift to maternal obesity. In conclusion, Cundy (2012) strongly
recommended that providers review the IADPSG criteria and compare the benefits to the risks
and costs associated with early universal and lower levels of detection, which will increase the
number of GDM diagnoses.
Hagar and Hod (2010) reviewed the process of GDM from defining the problem to the
end point of possibly achieving a world-wide policy change. GDM is associated with poorer
maternal and neonatal outcomes as well as morbidity. There is also speculation that long-term
exposure to hyperglycemia in utero may predispose the infant to obesity and diabetes later in life.
Current diagnostic criteria are more than 40 years old and were often based on non-pregnant
populations. The major issue is the lack of correlation of the criteria to actual maternal and
neonatal outcomes. The elusive questions are what is the true diabetic threshold for
hyperglycemia in pregnancy and at what point is there a risk to the fetus? There are numerous
other factors that can affect the health of the fetus such as maternal age, weight, hypertension,
previous GDM, macrosomia, and other medical complications. In addition, there is the risk of
under diagnosis of diabetes with the current criteria that may lead to avoidable adverse

25
outcomes. Controversy also revolves around screening or not screening as well as when to screen
and what type of screening to utilize. The HAPO study was conducted to help answer some of
these questions. The IADPSG reviewed multiple studies, including the HAPO study, and
developed a strategy for detection and diagnosis of hyperglycemia in pregnancy. The
recommendations focused on early testing at the first prenatal visit to detect overt diabetes as
well as on those women who are at high risk for developing GDM. The second phase focused on
the remaining non GDM population and recommended a 75-gram, 2-hour OGTT between 24 and
28 weeks gestation. At some point, another form of testing may be developed that is simpler and
more cost effective than the OGTT. Ultimately, these recommendations if put into practice will
increase the frequency of a GDM diagnosis (Hagar & Hod, 2010).
The AHRQ (2012) conducted a literature review to evaluate current screening tests for
GDM, time of screening, various diagnostic thresholds, and to determine if modifying treatment
will have an effect on outcomes for those diagnosed with GDM. The review was also searching
for previous evidence gaps that have been resolved. These gaps included determining if maternal
and fetal complications were reduced by screening, lack of screening studies to evaluate health
outcomes, evidence regarding accuracy of screening, and insufficient evidence that treating
GDM would improve health outcomes. Five key questions were developed to synthesize the
evidence found and to provide information as treatment guidelines were developed. They
reviewed studies published between 1995 and 2012, which included 14,398 citations and 97
studies. The review determined that there are limited data to clarify issues regarding the timing
of screening, before or after 24 weeks gestation, and treatment for GDM. In addition, the
evidence also fails to establish a clear threshold regarding diagnostic criteria for GDM. The
study did acknowledge the importance of identifying overt diabetes even if in pregnancy and that
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it should not be considered GDM to help identify the true risk of GDM for pregnancy outcomes;
however, there are no diagnostic criteria to diagnosis overt diabetes in pregnancy. The evidence
found also was not sufficient to provide evidence that there is a direct link between macrosomia
and childhood obesity. The review identified several gaps in the current literature that need to be
clarified to determine the true effect of maternal hyperglycemia on long-term metabolic
outcome, and the true effect of GDM treatment on outcomes, especially if initiated before 24
weeks gestation. In addition, there was emphasis on the need to identify how to diagnose and
treat the overt diabetic who is diagnosed during pregnancy. The goal of the review was to fill in
gaps in the research but, ultimately, found there are still several important gaps in need of
clarification in order to resolve the current controversies so that global diagnostic screening
criteria and management of hyperglycemia in pregnancy can be established (AHRQ, 2012).
In 2010, the Joslin Diabetes Center and Joslin Clinic published guidelines for detection
and management of diabetes in pregnancy. The purpose of the guidelines was to assist physicians
in establishing individualized plans for hyperglycemia in pregnancy. The guidelines were
established after a review of the current literature, current practice, and clinical practice with the
goal of improving pregnancy outcomes. The guidelines outlined care for pre-existing diabetes,
GDM, nutritional therapy for both pre-existing diabetes and GDM, and post-partum care. The
Joslin Center recommendations included universal screening for all pregnant women at the first
prenatal visit with a FBS, RBS, or HbA1C unless they are identified as high risk. If high risk, the
woman will complete a 75-gram, 2-hour OGTT as soon as possible (Joslin Diabetes Center,
2010).
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Diabetes Management Reviews
Abayomi, Wood, Spelman, Morrison, and Purewal (2013) provided an overview of a
multidisciplinary approach for the management of Type 2 diabetes and GDM in pregnancy. The
first step in a multidisciplinary approach is pre-conception care, which is lacking for a large
number of women. They found that less than 17% of the maternity clinics offered a structured,
multidisciplinary service for pregnant women that includes information on glycemic control,
diet, contraception, supplementation, and alcohol-related complications. It was determined that
all women with diabetes should have access to a multidisciplinary team which included an
obstetrician, a diabetes physician, a diabetes specialist nurse, a diabetes specialist midwife, and a
dietician. Women with Type 2 diabetes and GDM should be referred for education and followed
very closely throughout the pregnancy to ensure optimal glycemic control and outcomes for both
the mother and the baby. The team will be important during the delivery and post-partum phases
as well to ensure optimal care and outcomes. Prior to discharge, it will be very important to
provide contraception and follow-up information to prevent another pregnancy as well as ensure
monitoring for future development of Type 2 diabetes. With increasing numbers of metabolic
disorders, the multidisciplinary approach will help to ensure optimal care is provided to meet the
needs of the woman with hyperglycemia in pregnancy (Abayomi et al., 2013).
The Project Dulce model combined pieces of the chronic care model and the medical
home model to create primary homes where these models could be integrated and implemented
to improve outcomes associated with chronic diseases such as diabetes. Project Dulce used a
patient registry to identify patients at risk for diabetes, and then trained diabetes registered nurses
(RN/CDEs) to lead a multidisciplinary team to provide evidence-based care in community health
centers. Registered dieticians, medical assistants, and peer educators combined with the RNs to
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make up the multidisciplinary team. Ultimately, this was a nurse-driven approach to chronic care
management in the community setting for the underserved “at risk” populations. The nurse
driven approach was not only economical and effective, but it has demonstrated significant
improvement in diabetes and overall health outcomes (Philis-Tsimikas et al., 2012).
The nurse’s role in managing the overall care of diabetics is growing, especially as the
number of patients affected by diabetes continues to climb. Nurses can provide tools and
strategies to help empower many diabetics who often feel hopeless. Improving glycemic control
can be obtained through education by teaching the diabetic patient how to live with and
successfully manage their diabetes every day while living their life. In addition, nurses are the
largest population of healthcare providers and, therefore, will come in contact with more patients
across the spectrum of healthcare. As a result, nurses must participate in all aspects of diabetes
from screening to treatment. Education will play a vital role in all phases. Nurses educate about
the disease, how to test and monitor blood sugar levels, how to treat both high and low blood
sugar levels, how to make adaptations in diet and exercise, and how to manage the disease on a
daily basis. In addition, nurses play an important role in the monitoring of diabetic patients with
not only their blood sugar levels but also with ensuring appropriate physician follow-up and
testing related to their diabetes (Peimani, Tabatabaei-Malazy, & Pajouhi, 2010).
Context of the Project

WMC is a 445-bed, nonprofit hospital and Level 2 trauma center located in Winchester,
Virginia, which serves over 400,000 residents in Virginia and parts of West Virginia and
Maryland. WMC is a Magnet-designated hospital and 1 of the 6 hospitals within the non-profit
organization known as VH (Valley Health, 2014). In addition to the 6 hospitals, VH has 3 urgent
care centers, 1 quick care, center, 1 surgi-center, and Valley Regional Enterprises, Incorporated,
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which includes Valley Home Care, Valley Medical Transport, and Valley Pharmacy. In 2012,
VH had 30,000 inpatient admissions, over 140,000 emergency room visits, approximately
800,000 outpatient visits, and more than 2,600 births (Valley Health, 2014).
All hospitals within VH share the same mission and vision. The VH mission is “Serving
Our Community by Improving Health” and the vision is “One System - One Purpose: Leading
with Innovative Healthcare” (Valley Health, 2014, para. 1). Diabetes Management Programs are
established at all six VH hospitals, ADA certified, and share the same mission to “ . . . serve our
regional community by educating and supporting individuals with, or at risk for diabetes and
their family members.” The DMPs offer outpatient services provided by CDEs such as medical
nutrition therapy, diabetes education, gestational diabetes education, and individual consultations
(Valley Health Intranet, 2014, para. 1).

Governing Bodies
Health care is dictated by several governing agencies that establish practice
recommendations and guidelines, as well as provide national benchmarks for healthcare
organizations to meet or exceed. A few of the organizations affecting pregnancy and labor and
delivery include the Joint Commission (TJC), Medicaid and Medicare Services (CMS), ACOG,
and the Association of Women’s Health, Obstetric, and Neonatal Nurses (AWHONN). In
addition to governing bodies affecting healthcare and patient outcomes, healthcare reform
continues to play a role in clinical practice and the development and/or revitalization of current
programs (AWHONN, 2013).
Healthcare reform is centered on improving patient outcomes as well as increasing
overall productivity of healthcare in general. As a result, the AWHONN has been challenged to
develop nursing care quality (NCQ) measures that are aimed at improving patient outcomes. An
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advisory panel was convened in 2012 to develop the NCQ measures that are currently being
distributed for review. Many of the NCQ measures align with other governing organizations;
however, the NCQ measures focus on how nursing may affect patient outcomes and quality of
care (AWHONN, 2013).
Stakeholders
Stakeholders are individuals who have a vested interest in the project and who can help to
ensure it is accurate, relevant, and useful (AHRQ, 2011) Key stakeholders identified in this
project include the CDEs, obstetric providers (physicians, nurse practitioners, and registered
nurses), maternal and fetal medicine physicians, and the WMC senior leadership. Senior
leadership specifically involved in the project consisted of the interim director of the DMP, the
director of the Chronic Disease Resource Center, the physician liaison for the DMP, the
executive director of medicine, the executive director of women and children, and the physician
liaison for pregnancy outcomes.
Practicing as a medical/surgical nurse has provided me with extensive opportunity to
work with diabetic patients and witness firsthand the struggles of management while
hospitalized. Based on this experience, when the opportunity arose to participate in a committee
challenged to improve glycemic control for the inpatient population, I was quick to volunteer as
the educator on the committee. While on this committee, I had the opportunity to implement a
change in clinical practice regarding the approach to inpatient glycemic control from a sliding
scale approach to a basal-bolus approach. Basically, the new basal-bolus order set took a
proactive approach to treating diabetes compared to the sliding scale reactive approach. In
addition, the committee determined the need for registered nurse diabetes champions on every
unit. A conference was developed to educate nurses on diabetes and their role as a champion. As
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a result of working on this committee, it was clear that I wanted to do a DNP project related to
diabetes.
The project needs of the DMP were discussed and, after researching each of the topics,
this researcher was curious about GDM as well as surprised at the amount of controversy among
the governing bodies. Therefore, this researcher felt the need to develop a project aimed at
improving outcomes related to GDM. I participated in the literature review to determine the best
practices in screening and the diagnostic criteria for GDM as well as the revision of the Center’s
guidelines and the presentation to the obstetricians for feedback and approval. I also assisted in
content review for the three-day education sessions as well as the development and piloting of
the pretest and posttest questionnaires and the client satisfaction survey. Previous experience as
an educator at WMC has been instrumental in navigating the computer system, identifying
resources, reviewing policies/procedures, and questioning clinical contacts, while expanding my
knowledge of obstetrics.
Summary
Controversies remain on how to diagnose and manage hyperglycemia in pregnancy. Gaps
in research continue to exist especially with regards to the effects of early screening, how to
diagnose and manage the undiagnosed overt diabetic, and the effects of GDM on adverse
outcomes and future health outcomes. There was much support in the organization for the new
IADPSG guidelines to screen all women at the first prenatal visit and to lower the diagnostic
criteria threshold from greater than 95 mg/dL to greater than 92 mg/dL. However, there were
some concerns with the implications for healthcare and women. The concerns include the
implications of early screening, increased numbers of GDM diagnoses, and the financial
implications. Nurses play an important role in chronic care management but especially in
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diabetes care. Many diabetes programs are nurse-led and play a vital role in the overall
management of diabetes but also of the patient’s overall health. This project will help establish
the effectiveness of GDM education provided through one-on-one consultation and classroom
education provided by CDEs.
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Section 3: Methodology
The purpose of this project was to use the newly established guidelines in a clinic setting
for screening hyperglycemia in pregnancy to ensure that patients with GDM will be identified
earlier and will be able to begin education and implement other interventions/treatments earlier
in gestation. This paper discusses the project approach, sample, and participants, and it outlines
the step-by-step data collection process. In addition, a budget and a program evaluation plan are
provided.
Approach and Rationale
Six sigma methodology was created by Motorola, but it has been adopted and utilized
throughout health care. Six sigma provides a well organized and systematic approach for process
improvement that revolves around statistics and scientific methods to facilitate necessary change.
The philosophical underpinnings of the six sigma approach include problem identification,
measurement, statistical analysis, improvement, and controls. Within health care, six sigma has
been utilized to facilitate change in programs regarding hand hygiene compliance, surgery
turnaround times, clinic appointment access, catheter-related bloodstream infections, antibiotic
prophylaxis in surgery, meeting Centers for Medicare and Medicaid Services cardiac indicators,
nosocomial urinary tract infections, and operating room throughput. The broad applicability of
the six sigma methodology allows for easy adaptability and adoption (Vest & Gamm, 2009).
Six sigma utilizes the DMAIC methodology, which stands for define, measure, analyze,
improve, and control. The process began with defining the goal and overall scope of the project
and then created baseline evidence for comparison. The next phase was to monitor the
performance continuously and collect data that was used to analyze and interpret whether the
performances and/or outcomes wee as expected or if change need to be made. The final stage
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was to remove the actual cause of the problem so the focus can stay on the actual improvement
(Brandyopadhyay & Coppens, 2005).
With regard to this project, the six sigma approach provided the evaluation plan/tool to
determine the effectiveness of the 3-day education program completed by the project
participants. Continuous support and evaluation took place for the CDEs and pretests and
posttests were utilized to evaluate the patients’ perceptions and knowledge. The methods to
gather patient data included completion of pretest and posttest questionnaires to measure the
effectiveness of the educational intervention and a survey to determine satisfaction with the
education provided. On completion of data collection, I analyzed the data and determined
recommendations for revisions to the education program.
Project Setting and Sample Population
Regardless of the controversies about screening tests, the guidelines for hyperglycemia in
pregnancy at WMC were in need of revision as they were based on a combination of 1999
recommendations from ACOG, the International Diabetes Center, and the ADA. At that time, the
recommendations were to screen pregnant women between 24 and 28 weeks gestation with a 50gram glucose challenge; however, if the woman had one or more risk factors, it was
recommended to screen for GDM at the first prenatal visit. In addition, the practice physicians
were not using consistent glucose levels to diagnose GDM; therefore, another goal was to
establish standardization among glucose levels for diagnosing a pregnant woman with GDM
within the clinic. While working closely with the interim director of the DMP and the physician
liaison for maternal and fetal outcomes, new guidelines were established based on the review of
the literature, opinions of the team, and the population trends. The ultimate goal was to identify
pregnant women early in their pregnancy to provide early referral for nurse-led education that
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could play a role in improving the overall health outcomes for the mothers and their unborn
children. Expected project outcomes were established to reflect the effectiveness of the nurse-led
education by evaluating the knowledge gained by the participants regarding when to contact their
physician for abnormal blood sugar results and appropriate dietary choices.
The population was one of convenience and included all pregnant women referred by a
local obstetrician to the DMP with an abnormal glucose result. For the women to be included in
the study, they completed a GDM consultation with a CDE and completed the 3-day education.
Previously diagnosed Type 1 and Type 2 diabetics were excluded from the population sample as
well as women who do not complete the consultation and education requirement. The goal was
to have a minimum sample population of 30 women. The post-implementation population
included all women who attended the GDM class during a 6-week period after Institutional
Review Board (IRB) approval in February 2015.
Participants
Key participants in this project included the CDEs, obstetric providers (physicians, nurse
practitioners, and registered nurses), maternal and fetal medicine physicians, and WMC senior
leadership. In the infancy stages of the project, it was presented to the CDEs at the monthly
Gestational Council meeting. The goal was to solicit feedback as well as cooperation as the
project moved forward. Several meetings took place with the maternal/fetal medicine physicians
to revise the hyperglycemia in pregnancy guidelines due to the current guidelines no longer
being consistent with national practice recommendations. The revised guidelines were presented
to the obstetricians (OB) for review at the monthly department meeting by the physician liaison
for pregnancy outcomes. In October 2013, the guidelines as well as a timeline for
implementation were presented at the OB department meeting for formal adoption in January
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2014. The DMP interim director and the Director of the Chronic Disease Resource Center were
key participants in the project and played an integral role in access to the physicians, CDEs, and
patient information. Meetings have also taken place with the Director of Women and Children
Services and the Executive Director of Medicine to discuss the project, current data collection
plans, and concerns with maternal hyperglycemia and infant hypoglycemia outcomes. The new
guidelines were implemented January 1, 2014.
Stakeholders
An open relationship was established early on with many of the stakeholders to ensure
optimal success. The CDEs, OBs, fetal and maternal specialists, and the nurses and office staff
played an integral role in the effectiveness of the project and improving patient outcomes.
Attendance at the OB departmental meeting to discuss and present the timeline for
implementation allowed the OBs an opportunity to discuss concerns or suggest possible
revisions. In addition, I offered to hold in-services for the OBs and their office staff to provide
education on the new guidelines as well as how to facilitate a smooth transition with the changes.
I attended the OB departmental meeting in April 2014 to follow-up after the first quarter of
project implementation of the guidelines.
Data Collection
Pretest and posttest questionnaires were used to collect data from women with a
diagnosis of GDM who participated in the educational session to evaluate the comprehension of
class material regarding when to notify their physician with blood sugar readings as well as the
necessary changes to their diet. The pretest and posttest questionnaires are provided in Appendix
F. Walden University IRB approval was obtained prior to data collection.
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Reliability and Validity
In order to establish survey reliability, the CDEs who are considered content experts
reviewed the pretest, posttest, and satisfaction survey and provided feedback for revision. After
the pretest, posttest, and satisfaction survey were deemed appropriate, the questionnaires were
given to the GDM patients in December 2013 to establish validity prior to the new guidelines
being implemented in January 2014. The validity testing timeline was extended through March
2013 as the patient population was very limited due to inclement weather, the holidays, and the
relocation of the DMP. In April 2014, the completed pretests and posttests were evaluated by the
CDEs and me with regard to the clarity of the questions, patient success in completing the
surveys, and written comments. Based on the evaluation, the wording and/or answers were
changed on two of the questions to prevent any confusion. Steps to limit threats to reliability and
validity included having a consistent group of CDEs involved in the project from the beginning
as well as testing the instrument prior to full implementation. A copy of the initial pretest/posttest
is attached in Appendix D and the final version of the pretest/posttest is attached in Appendix F.
Data Collection Process
Currently, a pregnancy assessment is completed during a one-on-one consultation with a
CDE that includes questions regarding type and timing of GDM screening, medical and
pregnancy history, family history, and current diet to include food and beverages consumed on a
daily basis. The consultation also includes a nutrition consultation to determine caloric needs
based on pre-pregnancy BMI, weeks of gestation, and presence of multiples. This assessment
provided data related to physician compliance with the new GDM screening guidelines of
conducting an HbA1C at the first prenatal visit.
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The patients with GDM will also attended a class that includes education on diabetes,
blood glucose and ketone monitoring instructions, food and beverage choices, and guidelines for
physician notification. The patients completed the pretest and posttest as part of the GDM
classes, which will provide the data for patient knowledge regarding when to notify the provider
of abnormal blood glucose values as well as the data necessary to determine comprehension of
nutrition educational content. No patient demographic data will be collected. The data as well as
best practice recommendations will be presented to the stakeholders. The plan was to present the
data to the CDEs and the Executive Directors’ of Medicine and Women and Children.
Performance measurement was an ongoing process that began at implementation and
continued throughout the project to ensure success as identified through improved health
outcomes for the mother and the baby. During the month of January (2014), informal checks
took place with the CDEs as well as the obstetric providers to monitor compliance with the new
guidelines and to provide support through the change. In April 2014, feedback was formally
solicited at the obstetric department meeting.
The short-term effect of the project was to increase patient understanding of GDM selfmanagement during their pregnancy. The intermediate effect of the program was to improve
glycemic control of pregnant mothers throughout their pregnancy in order to decrease pregnancy
complications such as LGA, macrosomia, and infant hypoglycemia rates. Long-term health
benefits are related to a decrease in risk for future development of Type 2 diabetes for both the
mother and the infant as well as a decreased risk of childhood obesity (Metzger, 2010).
Data Analysis
Data from the pretest and posttest questionnaires and the patient satisfaction survey was
entered into SPSS and was analyzed using descriptive statistics such as frequencies and
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percentages. A t test was used to determine if posttest scores were significantly higher than
pretest scores on the self-management knowledge questionnaire.
Resource and Time Restraints
The initial resource constraint could be due to providers not following the new guidelines
and not conducting screenings for GDM at the first prenatal visit. A later screening would delay
a referral for education and intervention and reduce the number of participants. The GDM
classes were to be held six times a month which also limits the possible number of participants as
each class is limited to eight women. In addition, the participants must actually show up for their
consultation and class before they can be included as participants. Unfortunately, people were no
shows on a regular basis causing class sizes at times to be very small. In 2013, 121 women did
not show for the class, and in 2014 119 women were no shows for the classes. All participants
who attended a GDM consultation and education class were invited to participate, with a goal of
recruiting at least 30 participants. Time constraints were a final issue due to the timeline of the
DNP program.
Budget
In order to start an education program for GDM, a budget was established. Due to the classes
being in an existing outpatient DMP office, the actual startup costs were minimal. Initial
purchases for computers, copier, AV equipment, desks, telephones, and office supplies were not
be necessary as the outpatient office already exists; however, actual expenses included both labor
and materials. Labor included office staff and CDEs. The material expenses included office
supplies such as paper, folders, pens, pencils, and flow sheets as well as snacks such as peanut
butter, crackers, milk, juice, and water for the clients who attended the education class The
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majority of the educational material were provided free of charge by various pharmaceutical
companies and the National Institute of Health.
Table 1
Proposed Budget
Revenue per
Revenue

Consultation fee

Class fee

month

Semiannual revenue

Insurance and

$80

$180

$9,360

$56,160

mdicare
Hours Per
Expenses

Expenses per

Semiannual

Per class

month

wage

month

expenses

2

24

$11

$528

$3,168

56

$34

$1,904

$11,424

$2432

$14,592

$10

$60

$36

$216

$46

$276

patients

$1,560

$9,360

Total expenses

$4,152

$24,912

Office
employees
CDEs

Total labor
Snacks

Office supplies
1
Total material
Uninsured
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Table 2
Profit/Loss
Month

Semiannual

Total revenue

$9,630

$56,160

Total expenses

$4,152

$24,912

Profit/(loss)

$5,478

$31,248

Classes were held every Friday and every other Tuesday equaling six classes per month with
an average of six clients per class for a total of 36 women per month. The uninsured clients were
considered in the equation as there was no reimbursement for those clients. No client was turned
away and the cost of the consult and class was written off for the uninsured clients. Based on
15.4% of Americans being uninsured that equaled approximately six clients per month and 36
clients over 6 months (Kaiser, 2013).
Evaluation Plan
A specific evaluation plan was necessary to serve as a guide through the various steps of
evaluation while ensuring the appropriate data were collected in a timely manner. Upon project
completion, the data were evaluated and presented to the stakeholders (Hodges & Videto, 2011).
As mentioned above, in January 2014 the new guidelines for managing hyperglycemia in
pregnancy were implemented among all obstetric providers and CDEs within the Valley Health
System.
Beginning in February 2014, informal checks with the obstetric providers took place to
answer questions, offer assistance, and briefly evaluate if all pregnant women were receiving the
GDM screening at their first prenatal visit. After Walden University IRB approval, the pretest
and posttest data were collected and analyzed to measure whether patients’ knowledge of the
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GDM increased upon completion of education. All data were reviewed to evaluate the effects of
the new program and determine possible recommendations for change.

Figure 1. Process flow timeline.
Summary
Hyperglycemia in pregnancy is a serious complication of pregnancy with implications for
both the mother and the fetus even after delivery due to the increased risk of developing Type 2
diabetes (Metzger, 2012). A program designed to help educate on diet, exercise, and monitoring
was expected to help improve overall glycemic control, which in turn will reduce hyperglycemia
associated complications. Six sigma methodology was utilized to achieve the goal of the project.
The evaluation measured the program effectiveness based on the pretest/posttests and a
satisfaction survey to evaluate the service provided. The budget provided above demonstrated
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that the benefits of the GDM program overall should out way the minimal associated costs.
Section 4 will further discuss the evaluation and findings based on the data collection outlined
above. Implications regarding the data, the new guidelines, and the program will be outlined as
well as the overall strengths and weakness of the project. A self-analysis is also included.
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Section 4: Findings, Discussion and Implications
The purpose of this DNP project was to use the newly established guidelines in a clinic
setting for screening hyperglycemia in pregnancy to ensure that patients with GDM will be
identified earlier and will be able to begin education and implement other
interventions/treatments earlier in gestation. Expected project outcomes were established to
reflect the effectiveness of the nurse-led education by evaluating the knowledge gained by the
participants regarding when to contact their physician for abnormal blood sugar results and
appropriate dietary choices. The ultimate goal was to identify pregnant women early in their
pregnancy to provide early referral for nurse-led education that could play a vital role in
improving the overall health outcomes for the mothers and their unborn children.
The project took place during a 6-week period between February and April 2015. The
intended sample size was 30 women with GDM who were referred for GDM education but
ultimately included 37 women with 35 fulfilling the requirements of completing the pretest,
posttest, and the patient satisfaction survey. The first outcome of the project was to ensure that
women receiving care in the project clinic were screened for GDM during the first trimester of
their pregnancy. Of the 35 participants, 20 women (57% of the sample) were screened prior to 20
weeks gestation. Two different obstetric practices, which included 11 different practitioners,
referred patients for GDM education. Five of the practitioners referred patients both prior to 20
weeks gestation and after 20 weeks gestation. Four of the practitioners solely referred women
prior to 20 weeks gestation where only two practitioners solely referred after 20 weeks gestation.
With regard to the pretest and posttest of the 35 participants, the mean pretest score was
75.43 with a standard deviation of 15.782. The scores on the pretest ranged from 40 to 100
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points. The posttest mean score was 91.71 with a standard deviation of 10.706. The posttest
scores ranged from 60 to 100 points. The pretest/posttest is provided in Appendix F.
Table 3
Statistics
Pretest
N

Valid

Posttest

35

35

Mean

75.43

91.71

Median

80.00

90.00

80

100

15.782

10.706

-.607

-1.582

.398

.398

Minimum

40

60

Maximum

100

100

Mode
Std. Deviation
Skewness
Std. error of Skewness

The differences in results between the pretest and posttest by individual were significantly better
on the posttest (p > 0.000). This is demonstrated by the statistical charts below.
Table 4
Paired Samples Statistics
Mean

N

Std. deviation

Std. Error Mean

Pretest

75.43

35

15.782

2.668

Posttest

91.71

35

10.706

1.810

Pair 1

Table 5
Paired Sample Correlation
N
Pair 1

Pretest & posttest

Correlation
35

Sig.
.605

.000
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Table 6
Paired Samples Test
t

df

Paired differences

Sig.
(2 tailed)

Standard.

Mean

Standard

error

95% Confidence interval of

deviation

mean

the differences
Lower

Upper

PretestPair

posttest

-16.286

12.623

2.134

-20.622

-11.950

-7.633

34

1

The participants also completed a patient satisfaction survey (Appendix E), which
demonstrated high scores on all eight questions with regard to satisfaction of the class and
meeting class outcomes. The participants had the opportunity to provide additional comments.
Those comments included: “Very educating class,” “Excellent,” “Thank goodness for this class,
I would have not figured this out on my own. Thanks,” “Class was a little long,” “Very helpful,”
“Thanks,” “Great class,”, “Good info,” and “ Having this class before you begin testing would be
helpful in being able know how to range your blood sugar.”

.000
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Table 7
Statistics

Valid

Question

Question

Question

Question

Question

Question

Question

Question

1

2

3

4

5

6

7

8

37

37

37

37

37

37

37

37

1

1

1

1

1

1

1

1

Mean

5.00

4.97

4.95

5.00

4.78

4.78

4.81

4.81

Median

5.00

5.00

5.00

5.00

5.00

5.00

5.00

5.00

5

5

5

5

5

5

5

5

Std. deviation

.000

.164

.329

.000

.534

.479

.518

.518

Std. Error of skewness

.388

.388

.388

.388

.388

.388

.388

.388

Minimum

5

4

3

5

3

3

3

3

Maximum

5

5

5

5

5

5

5

5

-6.083

-6.083

-2.498

-2.203

-2.794

-2.794

N

Missing

Mode

Skewness

The theoretical framework utilized for this project was Kurt Lewin’s change theory. As
outlined above, the obstetric provider compliance with screening for GDM during the first
trimester was 57%, which presented a significant margin for improvement. As this study did not
investigate why the screening rate was only 57%, one can only assume that it was partially due to
physicians adjusting to new guidelines and with patients’ first appointment being outside the first
trimester. There remains work to be done with the physicians to encourage the use of the new
screening guidelines Change is difficult for many, but it is important to revisit the 3-step process
of change theory: unfreezing, moving, and refreezing. If the physicians do not truly believe in,
understand, or see the value in the guidelines, then it will be impossible for them to move and
refreeze with the process for GDM screening (Kaminski, 2011).
The study participants overall demonstrated an increased knowledge related to diet
choices and physician notification of blood sugar levels. What was not assessed with this study is
the actual change made by the participants. The participants may know what to eat, how often to
check blood sugars, and when to notify the physician but may choose not to make any changes.
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With no changes the mother and child will continue to be at a greater risk for complications
regardless of GDM education and significant improvement in posttest knowledge scores. The
hope is that the unfreezing step and beginning of the moving step took place during the GDM
class and are followed with full movement and refreezing as the participants go home and put
their new knowledge into practice (Kaminski, 2011)
Implications
Projects have the potential for practice implications and future research. This study in
itself has a social effect as the participants take their knowledge and put it into practice at home.
This will not only effect the participant but also her family and anyone in her social network.
Pregnancy is usually a very social event and people become interested and often seek out
information and/or strategies to improve their health during this time.
Effect on Practice/Action
The newly established guidelines for GDM screening have been utilized to an extent by
the providers. However, there is definitely room for improvement as the rate of screening prior to
20 weeks gestation was only 57%. This project did not investigate potential causes for the delay
in screening; therefore; physician compliance and timing of initial appointment may have played
a role in delay of screening. As physicians continue to adjust to the new guidelines, I expect to
see an increase in the percentage of women screened prior to 20 weeks gestation.
The GDM class was beneficial to the participants, but the actual long-term effectiveness
of the class is unknown. The CDEs will continue to track macrosomia and LGA rates to evaluate
potential positive implications from the GDM classes with regard to the delivery of large
neonates.
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Effect on Future Research
The project did substantiate both of the proposed outcomes; however, the need continues
for additional research to optimize the screening process for GDM as well as the GDM classes.
This is especially true for women being screened for GDM during their first trimester. Future
research could specifically track each physician and referral practices to identify any trends
and/or limitations leading to the delay in screening. As far as the effectiveness of the GDM
classes, future research could follow women who participated in the educational intervention
from the initial GDM screening throughout the pregnancy and even the delivery to evaluate
overall blood sugar management and fetal outcomes. In addition, the research could continue
long term to evaluate the probability of women with GDM and/or the macrosomia/LGA neonates
developing type 2 diabetes mellitus in the future.
Project Strengths and Limitations
Strengths of the project include consistency among the educators. The CDEs were trained
and certified in diabetes education and, therefore, maintained the required knowledge to present
the GDM classes. In addition, the sample size of 35 participants was larger than the originally
proposed sample size of 30. An accidental strength of the project was due to the delay in
implementation as it provided the physicians approximately a year to adjust to the new screening
guidelines prior to the project being implemented and screenings for GDM being measured.
Limitations
Limitations are a part of research and this project has proven no different. The participant
population was one of convenience, and even though the population size was larger than
originally proposed, it was still small in size. The length of the project could also be considered a
limitation as it was only conducted for 6 weeks. Considering that GDM classes take place every
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week, this time frame is short to obtain an accurate picture of the population. Another limitation
specifically related to the GDM class has to do with the number of week’s gestation of the
woman when she attended the classes and learned the information. For example, if a woman was
24 weeks gestation when she attended the classes and began managing her GDM, The outcomes
may be different from those of a woman who attended the classes at 12 weeks gestation.
Recommendations for remediation of limitations
Recommendations to overcome the limitations would include a larger sample size,
possibly through an alternative method than convenience sampling. In addition, lengthening the
time frame may help provide a more accurate picture of the population outcomes. Women not
showing up for the education continues to be a problem as there were eight no shows during the
project time frame. Reminder phone calls prior to each class either by a person or through
automaton may be beneficial in decreasing this number or help facilitate the women successfully
completing the education program. The final recommendation refers back to the timing of the
GDM screening taking place during the first trimester for all women to ensure early referral to
GDM education if deemed appropriate. The earlier these women receive education, the more
prepared they are to manage their GDM throughout their entire pregnancy. This could have a
substantial effect on neonatal outcomes related to GDM if blood sugars are well controlled
throughout the entire pregnancy.
Analysis of Self
Developing and conducting research is very exciting but also very challenging. The time
required is more than most could ever imagine but definitely worth it in the end. I had many
challenges throughout this process but found ways to overcome and persevere. It is interesting to
reflect and analyze yourself as a scholar, a practitioner, and as a project developer.
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As Scholar
As someone who was well versed in diabetes but not necessarily in GDM, this project
was very interesting and challenging. I have gained important knowledge in screening, treating,
and providing education for GDM. I also now possess the awareness and knowledge of the many
potential complications both mother and child may be subjected to as a result of poorly
controlled blood sugars.
As Practitioner
My main experience prior to this project and the doctoral practicum was focused on
inpatient management of diabetes mellitus. When working with an outpatient population, there
were many challenges to overcome, which were discovered throughout the implementation
process. Challenges identified in the outpatient setting include financial issues, lack of or limited
transportation, and lack of adequate health care and among many others. As a result, identifying
women during their first trimester of pregnancy for GDM can be very difficult, which can delay
GDM education.
As Project Developer
Project development is challenging and rigorous, but overall an educational experience
that cannot be obtained in any other format. I have a better understanding and appreciation of the
various steps necessary to conduct a quality project. The process starts with an idea and develops
into project with an implementation plan and identified project outcomes. Next, it involves IRB
approval, which is an experience in itself but very necessary not only to ensure valid
interventions but also to protect study participants. It is very exciting in the end to have the data,
analyze it, and determine if the project objectives were met. The final step is to evaluate the
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results and develop potential recommendations for the future. I will be more prepared for future
research endeavors as a result of this project.
Future Professional Development
I plan to continue with professional development in research; however, the research may
not necessarily be focused on hyperglycemia in pregnancy. The topic is very interesting and
important, but it no longer aligns with my professional focus. The research currently of interest is
related to nursing education and how to improve upon specific program outcomes as well as
improvements within the classroom. Simulation and alternative clinical experiences may also be
future research topics.
Recommendations
Project recommendations include continuing to screen for GDM in first trimester, but to
work with the obstetricians on how to improve the screening rate. Meeting with the obstetric
providers to discuss the current rate, why certain cases were not screened early, and possible
ways to improve the screening rate would help provide answers to important unanswered
questions as well as providing possible solutions. It is important to continue with early referral
for education, but it is also important to stress to the participants the importance of them
attending GDM education as soon as possible as it will provide important information and
guidance related to GDM. The CDEs should continue to monitor LGA and macrosomia rates but
may consider adding cesarean section rates, infant hypoglycemia admissions to the newborn
nursery, and NICU admissions due to infant hypoglycemia. Other data to consider collecting
would include complications rates of shoulder dystocia, hypertension, prematurity, and
preeclampsia.
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Summary and Conclusions
The purpose of this DNP project was to use newly established screening guidelines for
hyperglycemia in pregnancy to ensure that clinic patients with GDM will be identified during
their first trimester and begin education and other interventions/treatments earlier in gestation.
The project proposed that early detection of gestational diabetes and early referral for diabetes
education would improve the self-management and knowledge of pregnant women diagnosed
with GDM. The first project objective was partially met as 57% of the women were screened for
GDM prior to 20 weeks gestation. In addition, the education intervention resulted in a significant
improvement in knowledge of GDM and its management. These data met the second objective,
which was that the participating patients would learn when to contact their physician for
abnormal blood sugar results and appropriate dietary choices.
While beyond the scope of this project, the ultimate goal was to reduce complications
associated with GDM such as preterm labor, hypertension, preeclampsia, hemorrhage, and
shoulder dystocia, while decreasing adverse labor, delivery, and infant outcomes such as
macrosomia, LGA, cesarean delivery, and infant hypoglycemia. WMC statistics demonstrated a
decrease in caesarian sections rates from 37.4% in 2013 to 35.4% in 2014. January through April
2015 demonstrated a continuing decline in caesarian sections, currently at a rate of 34.3%.
Macrosomia rates decreased from 11.6% in 2013 to 10% in 2014; however, LGA rates increased
from 27.7% in 2013 to 28.3% in 2014. Infant hypoglycemia has also decreased from 18 newborn
nursery admissions in 2013 to 14 in 2014, with seven NICU admissions in 2013 down to five in
2014. Macrosomia, LGA, and infant hypoglycemia for 2015 are not yet available. As WMC has
demonstrated, a continuing decline in macrosomia and LGA as well as a decrease in newborn
nursery and NICU admissions for infant hypoglycemia, these results do correlate to the
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implantation of the new screening guidelines for hyperglycemia in pregnancy and project
implementation but cannot be directly attributed to the change in clinical practice or the decline
in presented data.
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Section 5: Dissemination of Scholarly Project Outcomes
The problem addressed by this project was the need for early identification of GDM and
educational intervention to improve the self-management and knowledge of pregnant women.
The purpose of this project was to use newly established guidelines for screening hyperglycemia
in pregnancy to ensure that patients with GDM will be identified during their first trimester and
begin education and other interventions/treatments earlier in gestation in the clinic setting. The
project proposed that early detection of gestational diabetes and early referral for diabetes
education would improve the self-management and knowledge of pregnant women diagnosed
with GDM. The anticipated outcomes of the project were:
1. Women receiving care in the project clinic will be screened for GDM during the first
trimester of their pregnancy.
2. The pretest scores compared to the posttest scores on a questionnaire to examine
knowledge of GDM and its treatment will demonstrate that the participating patients have
learned when to contact their physician for abnormal blood sugar results and appropriate
dietary choices.
Kurt Lewin’s planned change theory was selected as the theoretical framework for the
project. Lewin’s theory includes three elements: Field theory, Group Dynamics, and three step
model. Field theory and Group Dynamics are utilized during the three step mode of unfreezing,
moving, and refreezing to create and maintain change (Burnes, 2004). Changing one’s
views/perceptions is referred to as the process of unfreezing. The next stage is changing the
thoughts, feelings, and/or behaviors of the providers in order to introduce the revised practice
guidelines. The final stage is refreezing, which incorporates the changes and allows them to
become the new standard practice for all GDM patients (Kaminski, 2011).
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The six sigma approach was utilized for program evaluation. In healthcare, it is important
to include the patients’ perspectives or opinions regarding programs. One method was to
complete pre and post tests to measure the effectiveness and/or satisfaction with the service
provided. Six sigma utilizes the DMAIC methodology, which stands for define, measure,
analyze, improve, and control. The process begins with defining the goal and overall scope of the
project and then creating baseline evidence for comparison. The purpose of the next phase
(measure), was to continuously monitor the performance and collect data that will be used to
analyze and interpret whether the performances and/or outcomes are as expected (analyze) or if
change needs to be made (improve). The final stage (control) was to remove the actual cause of
the problem so the focus can stay on the actual improvement (Brandyopadhyay & Coppens.
2005).
The project and its results were presented to the CDEs, the Director of CDRC, and the
Executive Director of Medical Service Line, the Executive Director of Women and Children, and
the previous Interim Director of DMP utilizing a Power Point presentation. The Power Point is
provided in a separate document. After the presentation discussion began regarding physician
compliance and their observations of one physician group screening at first visit versus the
second group not being as consistent. One of those physicians one has now retired so they are
interested to see if he is replaced and if so will that help improve their compliance. This is the
same group that came up in discussion as the screening guidelines were being revamped as not
being as receptive or willing to follow. They would also like to see if there is a true correlation
between women who are screened, receive education, and manage their blood sugars with
maternal/fetal outcomes. Basically, following the participants through their entire pregnancy and
evaluating during the pregnancy and after delivery for both the mother and infant. At this time
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there are no plans for further research with regards this. I also do not believe they are planning to
continue the pretest and posttest. However they will continue with the consultation, education,
and satisfaction survey.
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Appendix B: Pregnancy and Diabetes Guidelines
SHENANDOAH VALLEY
MATERNAL
FETAL MEDICINE

PREGNANCY AND DIABETES
GUIDELINES

VALLEY
HEALTH

*** For management of pregnant women with pre-existing type 1 or type 2 diabetes, optional
local endocrinology referral and MFM fetal assessment OR complete diabetes management by
MFM. See below, page 3.
A. Screen all pregnant women on the first prenatal visit with serum HbgA1c.If the patient has
no risk factors listed below, her status is low risk. If she has one or more of the risk factors,
her status is high risk.
B. Historical risk factors (from completed maternal history)
1. Diabetes in a parent or sibling
2. Previous pregnancy with gestational diabetes
3. Previous child with birth weight > 4,000 grams
4. Stillbirth of unknown cause
5. Unexplained congenital malformations of a previous child (i.e., not due to a virus, toxin,
karyotypic abnormality).
6. Age >35 years
C. Physical risk factors (from initial and interim maternal/fetal assessments)
1. Obesity (BMI > 27)
2. Glucosuria (one specimen of 3+ or greater or two specimens of 2+ or greater)
3. Polyhydramnios
4. Large for gestational age fetus (>90 percent by ultrasound)
5. Complaint of hypoglycemic problems
6. Ethnicity: American Indian, African American, Asian American, Mexican/Hispanic and/or
Pacific Islander descent

SCREENING
1. Obtain a HgbA1c at NOB on all patients. **Patient does not need to be fasting for
HgbA1c.
2. If HgbA1c is ≥ is 6.5%, consider has pre-existing type 2 diabetes, previously
undiagnosed.
FYI- If HgbA1c is between 5.7-6.4% it is considered pre-diabetes in the non-pregnant.
Discuss diet.
3. If HgbA1c is < 6.5 and high risk, check fasting. If fasting is < 92 mg/dL, follow up as low risk.
4.

If HgbA1c is < 6.5 and patient is low risk, then (at 26-28 weeks) obtain 2-hour OGTT
with 75 gram load OR one hour 50 gram glucola test; if result ≥ 130 mg/dL, then 3-hour
OGTT.

DIAGNOSIS
A. Procedure for the 75 gram oral glucose tolerance test (OGTT) is “one-step testing”:
a. The patient should fast from midnight to the morning of the test.
b. A fasting serum sample should be obtained.
c. The patient is given 75 gm of Glucola orally and instructed not to eat, drink, smoke or
leave the waiting room until completion of the test.
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d. Plasma blood samples are drawn at 1 and 2 hours following ingestion of the test
solution.
B. Evaluating results of 2-hour 75 gram OGTT serum testing: (These values apply for serum and
plasma testing, not for whole blood.) If one or more value is elevated, then diagnosis of GDM.
FBS
abnormal value
1
abnormal value
2
abnormal value

≥92 mg/dL

-GDM one

hour postprandial ≥

180 mg/dL

-GDM one

hour postprandial ≥

153 mg/dL

-GDM one

*If fasting blood glucose result is ≥ 126 mg/dL, consider has pre-existing type 2 diabetes
mellitus. See below.
C. Procedure for the 50 gram glucola + 3-hour OGTT:
a. Fasting status not necessary; low carbohydrate meal recommended.
b. The patient is given 50 gram glucola orally and instructed not to eat, drink, smoke, or leave
the waiting room.
c.Serum sample at 1 hour.
d..Positive test if BG ≥ 130 mg/dL
e.If positive 50 gram result, then refer for 3-hour 100 gram OGTT.
Plasma fasting level drawn before the 100 gram glucose load.
The patient is given 100 gram glucola orally and instructed not to eat, drink, smoke
or leave the waiting room until completion of the test.
Serum samples at one, two and three hours.
Positive test is two or more elevated values = GDM
Fasting
1 hour
2 hour
3 hour

BG
BG
BG
BG

≥
≥
≥
≥

95 mg/dL
180 mg/dL
155 mg/dL

140 mg/dL

For pregnant women with a history of gastric bypass, plasma fasting and one hour postprandial is the
diagnostic test. Fasting BG should be less than 92 mg/dL and one hour post prandial BG should be less
than 140 mg/dL.
If a patient is not able to tolerate an OGTT or it is logistically too late to do an OGTT, then suggest a
serum fasting and one hour post prandial test. Fasting should be less than 92 mg/dL and one hour post
prandial BG should be less than 140 mg/dL.

MANAGEMENT OF GLUCOSE INTOLERANCE OF PREGNANCY
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ANTEPARTUM
A. Referral to outpatient Diabetes Management Program (DMP) for GDM class. This will include
instruction on BG monitoring and ketone testing, as well as nutrition consultation to determine
caloric needs
based on pre-pregnant BMI, weeks of gestation and presence of multiples. The DMP will offer
the patient
a one week follow-up appointment at the DMP.
B. Patient will perform self-monitoring of blood glucose four times a day; fasting and one hour
after meals.
(Post prandial reading is taken following the first bite of a meal.) The patient will initially
monitor urine
each morning with ketone dipstick. Provider can decrease ketone testing to three times a week
if all results
are negative. Patient to bring GDM flowsheet with BG and ketone results to all OB appointments
for
review by provider. OB provider can elect less frequent testing if blood sugars are normal after
two weeks.
C. If one hour post prandial BG readings are consistently ≥ 130 mg/dL, and/or fasting ≥ 92 mg/dL,
the
physician should consider oral Glyburide or insulin therapy. (Or, if the patient is already on
insulin,
adjustment of insulin therapy). Referral to MFM diabetes clinic recommended if insulin start is
needed.
The OB physician will be responsible for decision to initiate medical therapy for BG control.


Glyburide start dose 1.25-2.5 mg daily versus twice a day depending on when blood glucose is
elevated).
 The patient will call/fax BG flow sheet to primary OB or Shenandoah Valley MFM (if they
are consulted) every 2-3 days until fasting < 92 mg/dL, 1 hour <130 mg/dL.
 Thereafter, once BG readings are at goal, the patient will call/fax BG flowsheet to
managing practice weekly
 Office visits every two weeks with primary OB
 SVMFM diabetes clinic visit at least monthly if consulted
D. The patient will keep record of kick counts beginning at 28 weeks
E. Consider ultrasound for sizing at 30-32 weeks. If > 90 %, manage as macrosomia. If AC >75
%, consider insulin/glyburide therapy.
F. Begin antenatal testing at 34 weeks if pregnancy requires insulin or glyburide, if there is a
history of stillbirth, or have hypertension, macrosomia, or if there is evidence of poor
control.
G. If not on glyburide or insulin, begin NSTs at 40 weeks if undelivered.
H.

LABOR MANAGEMENT

68
A.
B.
C.
D.

What is your EFW?
No meds or meds and well-controlled: consider induction if undelivered by 40 weeks.
Meds and poor control delivery 34-39 weeks depending on compounding factors.
Ultrasound EFW if ≥ 4500 grams with GDM consider Cesarean section depending on
maternal size, pelvis and history of births.

POSTPARTUM
In hospital, check fasting postpartum day one if GDMA 2.

As outpatient in first year:
HgbA1c
≥ 6.5% referral to internal medicine
Random blood sugar ≥ 200
referral to internal medicine
Fasting blood sugar ≥ 126
referral to internal medicine

MANAGEMENT OF WOMEN WITH TYPE 1 & 2 DIABETES OR PATIENTS
REQUIRING
INSULIN MANAGEMENT BEFORE 20 WEEKS
INITIAL ORDERS
Ophthalmology referral in the first trimester and then per consultant’s recommendation.
Nutrition- diabetes management
Social work, if indicated
Referral to outpatient Diabetes Management Program for “pregnancy and diabetes”
education
E. If on insulin pump, referral to DMP for “insulin pump pregnancy and diabetes education”
F. Referral to Shenandoah Valley MFM Diabetes Clinic
A.
B.
C.
D.

Laboratory work:
A. Serum electrolytes, creatinine, BUN, GFR (Chem 14)
B. Urine culture
C. Baseline 24-hour urine for creatinine clearance and total protein
D. An initial HGB A1C should be drawn for assessing control over the 2-3 months to assist
with counseling regarding congenital malformations. Also use to check compliance
throughout pregnancy.
E. Consider EKG based on patient history (chest pain, MI, early FH MI), habits (cigarette
smoker), and age >35 years.
Management:
A. Glucometer instruction. Four times a day BG testing; fasting and one hour postprandial. If
poorly controlled, add before meal and bedtime testing; BG 7 times a day.
B. Teach family members/significant others about Glucagon treatment for hypoglycemia and
give patient prescription for glucagon kit.
C. Switch all women with preexisting Type 2 diabetes that were managed on oral agents to
insulin in the first trimester. Use NPH insulin for the basal and Humalog or NovoLog
insulins for the meal coverage. Because NPH is the most studied basal insulin in
pregnancy, it should be the first long-acting insulin offered to the patients. Switch patients
on Lantus to NPH insulin or Levemir insulin (1:1 conversion).- Both pregnancy category B.
D. 15-18 weeksConsider AFP due to increased OSB risk
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E.
F.
G.
H.

18-20 weeks22-26 weeks28 weeks28-30 weekshypertension

I.

30-32 weeks-

J. 32 weeks-

Perinatal ultrasound for anomalies
Fetal echocardiography
Kick counts
Weekly NST in all poorly-controlled Type I or if history of stillbirth, has
or has macrosomia
Perinatal ultrasound for predicting macrosomia
Repeat ophthalmologic examination if indicated
Two times weekly NST for those poorly-controlled.
Check amniotic fluid if non-reactive; consider OCT
Begin antenatal testing two times weekly for well-controlled diabetes

K. 34 weeks(Type I and II)
NST and AFI (2 x 2 pocket) or BPP
L. 39 weeksCervical check, induce if favorable
Classify 1. Good control
fasting

Deliver at 39-40 weeks if cervix is ripe and if average
< 85 mg % and 1-hour < 140 mg %.

2. Poor control (one of these)
1=
Pyelonephritis
5=
Macrosomia
2=
Ketoacidosis
6=
Polyhydramnios
3=
Preeclampsia
7=
Falling insulin
requirements
4=
Poor control
8=
Vascular
disease
Poor control- Consider delivery at 37-39 weeks.
INSULIN PUMP THERAPY: If patient is on insulin pump therapy prior to pregnancy, refer to
outpatient diabetes education for “insulin pump therapy adjustment and nutritional counseling
with pregnancy”. The Certified Pump Trainer (CPT) will attempt frequent communication and
follow-up with the patient and will alert the referring physician if the patient is not in
communication and/or is not following the plan of care. The CPT and the patient will establish a
plan of care for insulin pump adjustments for BG management during labor and delivery, and
post partum. If the patient is a candidate for insulin pump initiation during the pregnancy, refer
to outpatient diabetes education for evaluation of insulin pump therapy.
LABOR1. Monitor glucose with hourly BG testing with point of care testing (POCT).
2. Order urine for ketones if BG greater than 250 mg/dL in patient with pre-existing type 1
diabetes.
Bolus D5NS if > trace, then D5NS at 125 mL/hr and start insulin drip.
3. Insulin drip for blood glucose > 140 mg/dL
4. If epidural planned, load with normal saline
5. BG goal approximately 100 mg/dL
6. IV insulin drip orders: finger stick blood glucose monitoring q 1 hour

Start IV insulin drip at 1 unit/hr for blood glucose > 140 mg/dL.
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Pharmacy to mix insulin drip- regular insulin in N.S. 100 units in 100 cc NS.
For insulin drip:
< 100mg/dL, D/C drip. Restart when blood sugar > 140 mg/dL (if symptoms
bolus 150 cc D5NS)
If BG 140 – 180mg/dL, infuse at 1 unit/hr
If BG 181 – 220mg/dL, infuse at 2 units/hr
If BG 221 – 280mg/dL, infuse at 3 units/hr
If BG 281 – 350mg/dL, infuse at 4 units/hr
If BG greater than 350mg/dL, notify MD.
*If BG is greater than 220mg/dL for two consecutive hours, notify MD.
If scheduled induction, use one half of patient’s usual NPH dosing with breakfast, and usual
Humalog dose.
Check blood glucose hourly and dip all urine for ketones.
When blood glucose greater than 140mg/dL, begin IV insulin as above.
Avoid lactated ringers solution.
Cesarean delivery- NPO
No a.m. insulin. Treat post Cesarean section as per all
postpartum orders. Consider scheduling as early, am case.
POSTPARTUM- Type 1 and 2 Diabetes
1. Keep blood glucose < 200mg/dL
2. May use one half of patient’s pre-pregnancy regimen or sliding scale Humalog.
3. An insulin drip may help while a patient is NPO.
4. Discuss periconception control prior to next pregnancy

PRECONCEPTION GOALS
1.
2.
3.
4.
5.
6.

HgbA1C < 6.5%
Assess renal function
Folic acid
Check rubella
Encourage children within 10 years of diagnosis
Consider switching insulin to Humalog or NovoLog before each meal; with bedtime
dose of NPH insulin.
7. Treat retinopathy prior to conception; annual retinal exams for screening
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Appendix C: Literature Review Summary Table
Author

Aim

Sample

Method

Strength/Weakness

O’Sullivan,
Avalos,
O’Reilly,
Dennedy,
Gaffney, &
Dunne

Evaluate the
impact of new
diagnostic
criteria on
GDM
prevalence
and outcomes
in
predominantly European
populations.

5,500
women

Longitudinal casecontrol
study

Mehta, Kruger,
& Sokol

Determine if
relation exists
between
diabetes in
pregnancy and
childhood
obesity in
inner-city
AfricanAmerican
(AA)
population.
To estimate
the cost of
universal
screening for
GDM

493
mother
and
child
pairs

Longitudinal casecontrol
study

Large sample size,
identified that new
criteria is applicable to
European populations;
prevalence results
may not be as accurate
due to population
distribution higher in
age and BMI, no
consideration for
management of
hyperglycemic
treatment
Only study to show
IIa, B
association between
diabetes and
childhood obesity in
urban AA population;
retrospective study,
lack of information
about blood glucose
compliance, include
Type I, II, and GDM.

30,429
women

Longitudinal casecontrol
study

502
women

Longitudinal casecontrol

Gillespie,
O’Neill, Avalos,
O’Reilly, &
Dunne

Katon, Reiber,
To determine
Williams, Uanez, if HgA1C at
& Miller
time of GDM

Sample size, Included
estimates for
undiagnosed as well
as those diagnosed
with GDM, no
estimates for adverse
outcomes for the
mother or infant, no
consideration for
mother/infant
outcomes,
assumptions and
estimates – how
accurate?
Population diversity,
Standard GDM
diagnosis at 24 weeks

Level of
Research
IIa, B

IIa, B

IIa, B
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diagnosis is
associated
with increased
risk of LGA
or
macrosomia
infant
O’Connor,
O’Shea, Owens,
Carmody,
Avalos, Nestor,
& Dunne

Dall et al.

Van Dijk,
Verheij,
Swinkels,
Rijken,
Schellevis,
Groenewegen, &
Bakker

To establish
trimesterspecific
reference
intervals in
pregnancy for
IFCC
standardized
A1C in nondiabetic
Caucasian
women
Determine if
participation
intensity and
prior
indication of
uncontrolled
diabetes are
associated
with
healthcare use
and costs for
those enrolled
in
TRICARE’s
diabetes
management
program
Determine
what part of
total care
consumed by
Type 2
diabetes is
directly
related to

study

311
women

Randomised
controlled
trial

23,778
Quasipeople
experimenages 18 tal
to 64
living in
U.S.

208
selfreports
and
9,023
electronic
medi-

Descriptive
study

or greater gestation,
No considerations for
glycemic control in
third trimester could
explain null finding,
research took place in
two clinics which are
very aggressive in
treating GDM
Normal BMI,
determined that
semester specific A1C
references should be
utilized in pregnant
women

Ib, A

Sample size, Patients
IIb, B
chose level of
participation intensity,
Selection bias due to
highly motivated
individuals
participation, intensity
of participation, and
management of
disease; no
natural/true
comparison group, no
consideration for
external
education/information,
inability to determine
blood glucose control
Data collected from
III, B
different databases
that were not linked
and caused some
outcomes to be based
on a much smaller
sample size, identified
a gap in national
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Cavassini, Lima,
Calderon, &
Rudge

Metzer et al.

Catalano, et al.

Metzger et al.

diabetes and
the
implications
for disease
management
programs
Estimate costbenefit
relationship
and social
profitability
ratio of
hospitalization
compared to
outpatient
care for
pregnant
women with
diabetes
Clarify the
risks of
adverse
outcomes
associated
with various
degrees of
maternal
glucose
intolerance
less severe
than that in
overt DM.
Determine
associations
of GDM and
obesity with
adverse
pregnancy
outcome
Clarify the
risks of
adverse
outcomes
associated
with various
degrees of

cal
records

DMPs

50
women

Longitudinal casecontrol
study

Proved outpatient
management is more
cost effective than
inpatient, Small
sample size, no
consideration for oral
agents or insulin in
outpatient group, no
consideration of
adverse outcomes for
the mother or infant

25,500

Longitudinal casecontrol
study

25,505
women

Longitudinal casecontrol
study

Sample size, similarity
in results across the 15
centers in 9 countries
primary and
secondary adverse
outcomes considered,
nutritional status,
previous GDM,
maternal BMI,
previous macrosomia,
and gestation weight
gain were not
considered
Evaluates the impact
IIa, B
of GDM and obesity
but also their
combined impact on
adverse outcomes,
observational study

25,505
women

Longitudinal casecontrol
study

Large sample size,
nutritional status and
maternal weight gain
not considered,
Previous GDM, child
with macrosomia, and
maternal BMI may

IIa, B

IIa, B
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maternal
glucose
intolerance
less severe
than that in
overt diabetes
mellitus

have causally affected
adverse outcomes

Appendix D: Gestational Class Pre/Posttest Original

Gestational Diabetes Pre-Education Test
1.
A.
B.
C.
D.

Which of the following foods will affect your blood glucose the most:
French dressing, margarine, olive oil
Bread, orange juice and cereal
Cheese, cottage cheese and peanut butter
I don’t know

2.
A.
B.
C.
D.

When checking your urine for ketones, you would check your
First urine after midnight
Last urine before going to bed
First urine when getting up for the day
I don’t know

3. When checking your fasting blood sugar, you should notify your physician if
your blood sugar is consistently greater than
A. 75
B. 92
C. 85
D. 80
4. When checking your one hour blood sugar, you should notify your physician
if your blood sugar is consistently greater than:
A. 110
B. 120
C. 130
D. 140
5. When checking your blood sugar, you should notify your physician if your
blood sugar is consistently lower than
A. 70
B. 80
C. 90
D. 100
6.
A.
B.
C.
D.

A diabetes meal plan
Should consist of fruits, vegetables, proteins, and starches
Is a diet requiring special, expensive foods
Does not allow any starches or sweets
Allows unlimited starches and sweets

7.
A.
B.
C.
D.

One starch exchange is approximately
60 grams
30 grams
90 grams
15 grams

8.
A.
B.
C.
D.

A dairy exchange is
1 cup cottage cheese
1 cup milk
½ cup flavored yogurt
2 slices Swiss cheese

9.
A.
B.
C.
D.

Which of the following is one fruit exchange?
A large banana
A small apple
2 cups of blackberries
1 cup of applesauce

10. Which of the following is an example of one protein exchange?
A. 6 ounces of cooked lean chick, fish, or pork
B. 1 cup of tofu
C. 2 eggs
D. 2 TBSP peanut butter

Appendix E: Gestational Class Survey

Please rate each of the following from 1 to 5 with 1 being not at
all and 5 being always or completely.
1. Do you understand what gestational diabetes is and the effect that blood glucose
control has on the baby’s birth weight?
1
2
3
4
5
2. Do you know when to check your blood glucose?
1
2
3
4
5
3. Do you know how to check your blood glucose?
1
2
3
4
5
4. Do you know when to contact your physician with blood glucose readings?
1
2
3
4
5
5. Did this class meet your needs?
1
2
3
4
5
6. Based on what you learned today, do you know what changes to make in what
you eat and drink?
1
2
3
4
5
7. Did this class meet your expectations?
1
2
3
4
5
8. How would you rate this class overall?
1
2
3
4
5

Comments or suggestions:
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
______________________________
Thank you for your comments
Gestational Diabetes Class
rev. 11/16/13

Appendix F: Gestational Class Pre/Posttest Revised

Gestational Diabetes Pre-Education Test
1.
A.
B.
C.
D.

Which of the following foods will affect your blood glucose the most:
French dressing, margarine, olive oil
Bread, orange juice and cereal
Cheese, cottage cheese and peanut butter
I don’t know

2.
A.
B.
C.
D.

When checking your urine for ketones, you would check your
First urine after midnight
Last urine before going to bed
First urine when getting up for the day
I don’t know

3.

Checking your fasting blood sugar, you should notify your physician if your
blood sugar is consistently greater than
75
92
85
80

A.
B.
C.
D.

4. When checking your one hour blood sugar, you should notify your physician
if your blood sugar is consistently greater than:
A. 110
B. 120
C. 130
D. 140
5. When checking your blood sugar, you should notify your physician if your
blood sugar is consistently lower than
A. 70
B. 80
C. 90
D. 100
6.
A.
B.
C.
D.

A diabetes meal plan
Should consist of fruits, vegetables, proteins, and starches
Is a diet requiring special, expensive foods
Does not allow any starches or sweets
Allows unlimited starches and sweets

7.
A.
B.
C.
D.

One starch exchange is approximately
60 grams
30 grams
90 grams
15 grams

8.
A.
B.
C.
D.

A dairy exchange is
1 cup cottage cheese
1 cup milk
1 cup flavored yogurt
2 slices Swiss cheese

9.
A.
B.
C.
D.

Which of the following is one fruit exchange?
A large banana
A small apple
2 cups of blackberries
1 cup of applesauce

10. Which of the following is an example of one protein exchange?
A. 6 ounces of cooked lean chick, fish, or pork
B. 1 cup of tofu
C. 1 eggs
D. 2 TBSP peanut butter or any nut butter

Appendix G: Screening and Intervention Presentation

